



Lipid Profile Status and Cardiac Risk Factors in Opium Users Versus Non-users with Coronary Artery Disease: Insights from the National Persian Registry of Cardiovascular Disease (N-PROVE)

Sima Sobhani Shahri¹, Marzieh Heshmati¹, Seyed Ali Moezi Bady², Nahid Azdaki², Saeede Khosravi Bizhaem², Fahimeh Nikraftar³, Alireza Khosravi⁴, Toba Kazemi^{2,*}

¹ Student Research Committee, Birjand University of Medical Sciences, Birjand, IR Iran

² Cardiovascular Diseases Research Center, Birjand University of Medical Sciences, Birjand, IR Iran

³ Department of Nursing, Birjand Branch, Islamic Azad University, Birjand, IR Iran

⁴ Hypertension Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, IR Iran

*Corresponding Author: Cardiovascular Diseases Research Center, Birjand University of Medical Sciences, Birjand, IR Iran. Email: drtooba.kazemi@gmail.com

Received: 8 February, 2025; Revised: 8 March, 2025; Accepted: 9 March, 2025

Abstract

Background: Coronary artery disease (CAD) remains a leading cause of morbidity and mortality worldwide. Opium consumption is prevalent in certain populations and has various health implications, including potential effects on cardiovascular risk factors.

Objectives: This study aims to analyze the differences in cardiac risk factors, lipid profiles, and new lipid indices between opium consumers and non-consumers among patients undergoing coronary angiography.

Patients and Methods: This cross-sectional analytical study was conducted on patients who underwent coronary angiography at Razi Hospital in Birjand from March 2018 to March 2021. Participants included individuals with stenosis greater than 50% in at least one coronary artery. Patients were categorized into two groups: Opium consumers and non-consumers, based on self-reported usage during angiography. Data on demographics, medical history, Body Mass Index (BMI), and lipid profiles, including total cholesterol (TC), triglycerides (TG), low-density lipoprotein (LDL), and high-density lipoprotein (HDL), were extracted from patient records. New lipid indices were calculated using established formulas. All patients who underwent coronary angiography during this time frame were included in the study, ensuring a comprehensive sample. Descriptive statistics and comparative analyses were performed using SPSS software, version 22, considering a significance level of $P \leq 0.05$.

Results: Out of 1,888 patients with CAD, 24.5% were opium consumers. The mean age of opium users was lower than that of non-consumers (60.64 ± 11.14 years vs. 64.38 ± 11.38 years). A higher proportion were male (78.8% vs. 65.1%), and they had a lower BMI (24.67 ± 4.04 kg/m² vs. 25.46 ± 4.77 kg/m²). The history of hypertension, diabetes mellitus (DM), and dyslipidemia was less prevalent in opium consumers. Additionally, triglyceride levels, Atherogenic Index, Triglyceride-Glucose (TyG) Index, and non-HDL cholesterol were significantly lower in the opium group compared to the non-consumers. However, the history of coronary angioplasty and smoking was greater among opium users.

Conclusions: This study highlights the complex relationship between opium consumption and cardiovascular risk factors in coronary patients. Given the observed lower age and reduced risk factors among opium users, further research is warranted to confirm these findings and to investigate the potential role of opium as an independent risk factor for CAD. Understanding these dynamics is crucial for developing targeted prevention and treatment strategies in affected populations.

Keywords: Coronary Artery Disease (CAD), Opium Use, Dyslipidemia, Triglyceride Levels, Atherogenic Index (AI), Triglyceride-Glucose (TyG) Index

1. Background

Opioids are narcotic substances extracted from the poppy plant, and their misuse due to sedative effects dates back to 4000 B.C. (1). Currently, their prevalence is rising in certain parts of the world, including Iran (2), with a reported prevalence of 13.6% among adults in Babol (3). Recent studies indicate significant societal and health impacts due to increased opioid use, contributing to various health burdens across demographics. Opioids can affect different systems of

the body, including the central nervous, respiratory, and cardiovascular systems (4). Coronary artery disease (CAD) is the most common cause of mortality worldwide (5), with many individuals having at least one cardiovascular risk factor such as hypertension, smoking, dyslipidemia, obesity, and diabetes mellitus (DM). Research consistently highlights that adverse cardiovascular events can occur even in individuals with a normal lipid profile, emphasizing the need for comprehensive evaluations beyond traditional risk factors (6, 7). Therefore, new indices such as atherogenic

indices have been proposed. These indices, calculated using simple mathematical formulas, can indicate the severity of atherosclerosis and are useful in predicting the likelihood of CAD (8-12). The Atherogenic Index, also known as Castelli's Risk Index I and II (CRI I and CRI II), is derived from dividing total cholesterol (TC) or low-density lipoprotein (LDL) by high-density lipoprotein (HDL) (Table 1). This index has a direct relationship with cardiovascular events and is correlated with the thickness of the intima and media of the carotid artery, a sign of subclinical atherosclerosis (8, 9). Another index introduced for predicting the likelihood of atherosclerosis in coronary arteries is the Atherogenic Index of plasma (AIP) (10). High-density lipoprotein is recognized as a protective lipoprotein against CAD, while LDL is considered an atherogenic factor. Emerging evidence suggests that non-HDL may provide a more accurate measure for predicting atherosclerosis, as it encompasses all lipoproteins containing Apo B, which are implicated in atherogenesis (11). The Triglyceride-Glucose Index (TyG) is also an Alternative Index that indicates insulin resistance. This index is closely associated with the onset of non-communicable diseases such as hypertension, diabetes, CAD, stroke, obesity-related cancers, and even cardiovascular outcomes in diabetic patients (12). Statistics indicate that 36% of CAD patients in Iran consume opium (6). Various articles report different effects on the cardiovascular system and lipid profiles depending on the duration and amount of opium consumption. For instance, some studies indicate that prolonged opium use is associated with an increased risk for acute myocardial infarction and cardiovascular-related mortality (13). Conversely, other studies, such as that by Marmor et al., reported that opium consumption might confer a protective effect against cardiovascular diseases (14). There is also variability in the results regarding opium's effects on lipid profiles, with studies reporting significant lipid reductions, increases, or no impact compared to non-consumers (15-17).

2. Objectives

Therefore, considering the rising trend of addiction in society and the increasing prevalence of CVD and their risk factors, particularly dyslipidemia, along with the conflicting reports regarding the effects of opium on lipid profiles and risk factors for cardiovascular diseases, this study aims to clarify the relationship

between opium use and cardiovascular risk factors. It hypothesizes that opium consumers may exhibit distinct lipid profile changes and cardiovascular risk factor patterns compared to non-consumers.

3. Patients and Methods

3.1. Setting

The statistical population for this study comprised all eligible patients undergoing coronary angiography at Razi Hospital in Birjand, Iran, from March 2018 to March 2021. All patients who underwent coronary angiography during this time frame were included in the study, ensuring a comprehensive sample for analysis. Recruitment occurred during this period, with data collection following the angiography procedures. The study was conducted in compliance with ethical standards, and approval was obtained from the Ethics Committee of Birjand University of Medical Sciences (approval code: [IR.BUMS.REC.1401.171](#)).

3.2. Study Design

This cross-sectional study targeted patients diagnosed with significant coronary artery stenosis (greater than 50%) who underwent angiography. Patients were categorized into two groups: Opium consumers and non-consumers, based on self-reported opium usage at the time of angiography.

3.2.1. Inclusion Criteria

Eligible participants included adults aged 18 years or older with at least one coronary artery exhibiting stenosis greater than 50%, as confirmed through angiographic evaluation.

3.2.2. Exclusion Criteria

Individuals with significant comorbid conditions, such as advanced-stage heart failure or terminal illnesses, and those with cognitive impairments that could affect the reliability of self-reported consumption status were excluded from the study.

3.3. Variables

Outcomes of interest included lipid profiles, demographic information (age, gender), medical history, and Body Mass Index (BMI). The exposures were defined as opium consumption status (users vs. non-

Table 1. Definitions and Formulas for Lipid Indices

Lipid Indices	Formula	Normal Values ^a
CRI-I	TC/HDL	≥ 4
CRI-II	LDL/HDL	≥ 3
Non-HDL cholesterol (NHC)	TC - HDL	≥ 130
Atherogenic coefficient (AC)	Non-HDL/HDL	≥ 2
AIP	Log (TG/HDL)	≥ 0.1
TyG Index	Ln [TG × FBS/2]	≥ 9.04

Abbreviations: TC, total cholesterol; NHC, Non-HDL cholesterol; AC, atherogenic coefficient; TyG Index, Triglyceride-Glucose Index; LDL, low-density lipoprotein; HDL, high-density lipoprotein; AIP, Atherogenic Index of Plasma; CRI-I, Castelli's Risk Index I; CRI-II, Castelli's Risk Index II.

^a Regarded as high risk.

users). Potential confounders, such as age, gender, and comorbidities, were recorded to control for their effects in the analysis. Lipid profiles were measured through standard laboratory blood tests, assessing levels of TC, triglycerides (TG), LDL, and HDL. Demographic information was obtained through patient interviews and medical records, ensuring accurate reporting of age and gender. Medical history was collected via structured questionnaires detailing any previous diagnoses of cardiovascular diseases, hypertension, diabetes, and dyslipidemia. The BMI was calculated using the formula: Weight (kg)/height (m²), based on measured weight and height.

Please ensure that all references are correctly formatted according to the AMA style, as indicated by the numbers in parentheses if applicable.

3.4. Data Sources and Measurement

Data were systematically gathered from patient records using a structured checklist that included demographic details, medical history, BMI, and lipid profiles, including TC, TG, LDL, and HDL. Additionally, relevant angiographic data were extracted from the national online registry system for cardiovascular diseases (18). New lipid indices were calculated using established formulas outlined in Table 1 (8-12).

3.5. Handling Quantitative Variables

Quantitative variables were reported as mean ± standard deviation. Analyses included comparative statistics using appropriate methods, utilizing SPSS statistical software, version 22. For normally distributed

data, parametric tests were applied; for non-normally distributed data, non-parametric tests were utilized.

3.6. Statistical Analysis

Statistical analyses were conducted to compare qualitative variables using the chi-square test (or Fisher's exact test). The Kolmogorov-Smirnov test was employed to assess the normality of quantitative variables. Departures from normality prompted the use of the Mann-Whitney U test. A significance level of $P \leq 0.05$ was considered statistically significant. The specific statistical methods employed reflect an effort to control for confounding variables and enhance the robustness of the findings.

4. Results

Out of 3,479 individuals who underwent coronary angiography at Razi Hospital during the years 2018 - 2020, 1,888 patients had stenosis greater than 50% in at least one coronary artery. Additionally, 1,591 individuals with stenosis less than 50% in coronary arteries or lacking lipid profile or fasting blood sugar data were excluded from the study. Therefore, our study sample consisted of 1,888 individuals (Figure 1).

Out of the 1,888 patients included in the study, the majority were male (68.5%). Of these, 463 (24.5%) were opium consumers, and 1,425 (75.5%) were non-consumers. A comparison of demographic characteristics and medical history is presented in Table 2. The mean age of participants in the study was 63.46 ± 11.43 years. Opium consumers were approximately 4 years younger (60.14 ± 11.64 years) than non-consumers




Figure 1. Flowchart of study patients

(64.38 ± 11.74 years, $P < 0.001$). Additionally, non-opium consumers exhibited a significantly higher prevalence of hypertension (55.0%), DM (31.0%), and dyslipidemia (28.8%). In contrast, a history of previous percutaneous coronary intervention (PCI) and smoking was significantly higher among opium consumers. Laboratory factors in both groups are examined in Table 3. As shown, TG were significantly lower in opium consumers. The levels of fasting blood sugar, cholesterol, HDL, and LDL showed no significant differences between the two groups. Among the new indices, the AIP, TyG Index, and non-HDL were significantly lower in the opium-consuming group compared to the non-consumers. Other lipid indices did not show statistically significant differences between the groups.

5. Discussion

The overall prevalence of opium consumption among our CAD patients was 24.5%. In the study by Aghadavoudi et al. in Isfahan, which involved 325 patients undergoing coronary bypass surgery, the rate of opium consumption was reported to be 36%, and in the study by Davoodi et al., which explored 160 patients

with acute myocardial infarction in Tehran, it was 28.1% (6, 19). In the context of our study objectives, it is evident that opium consumption among CAD patients is prevalent and varies across different regions. This underlines the necessity of addressing substance use in the management of cardiovascular risks.

In the current study, the history of DM in opium consumers was lower than in non-consumers. The findings align with studies by Sheikhy et al. (20), Hamrah et al. (1), and Liew et al. (21), which also reported lower DM rates among opium users. Nalini et al. conducted a study on 40,083 participants in the Golestan Cohort Study, which took place from 2004 to 2008 in the Gorgan and Golestan region and involved a 12-year follow-up. The aim was to investigate the long-term relationship between DM and opium; thus, researchers excluded individuals with DM at the beginning of the study and then compared the incidence of DM among opium users and non-users. Results showed that individuals who used opium for a long time (average use duration of about 10 years) had a lower BMI (23.5% vs. 27%) and a lower waist circumference (88.9 cm vs. 95.7 cm), which were statistically significant. Furthermore, the incidence of

Table 2. Demographic Characteristics and Medical History of Study Participants in Opium Consumer and Non-consumer Groups ^{a, b}

Variables	Total (N = 1888)	Non-opium (N = 1425)	Opium (N = 463)	P-Value
Age (y)	63.46 ± 11.43	64.38 ± 11.74	60.14 ± 11.64	0.001 ^c
BMI	25.12 ± 4.73	25.46 ± 4.77	24.67 ± 4.04	0.001 ^c
Gender				0.001 ^c
Male	1293 (68.5)	928 (65.1)	365 (78.8)	
Female	595 (31.5)	497 (34.9)	98 (21.2)	
Risk factors				
Hypertension	977 (52.0)	780 (55.0)	197 (42.8)	0.001 ^c
DM	532 (28.3)	441 (31.0)	91 (19.6)	0.001 ^c
Dyslipidemia	515 (27.5)	410 (28.8)	105 (22.9)	0.009 ^c
Family history of CAD	352 (18.8)	267 (18.9)	85 (18.4)	0.822
History of CABG	92 (4.8)	69 (4.8)	23 (4.9)	0.974
History of PCI	271 (14.3)	191 (13.4)	80 (17.3)	0.049 ^c
Smoking status				0.001 ^c
No smoker	1605 (85.3)	1303 (91.7)	302 (65.5)	
Current smoker	204 (10.8)	83 (5.8)	121 (26.2)	
Recent smoker	73 (3.9)	35 (2.5)	38 (8.2)	

Abbreviations: CAD, coronary artery diseases; CABG, coronary artery bypass graft; PCI, percutaneous coronary intervention; BMI, Body Mass Index; DM, diabetes mellitus.

^a Values are expressed as mean ± SD or No. (%).

^b Statistical tests used in the table are Mann-Whitney test and 2 chi-square.

^c P < 0.05 was considered statistically significant.

Table 3. Comparison of Laboratory Factors and Indices in Opium Consumer and Non-consumer Groups ^{a, b}

Variables	Total	Non-opium	Opium	P-Value
TG	127.57 ± 83.56	131.53 ± 86.75	115.71 ± 59.37	0.001 ^c
Cholesterol	165.36 ± 36.81	166.14 ± 14.81	162.95 ± 100.83	0.09
LDL	100.15 ± 28.42	101.14 ± 41.73	97.33 ± 10.97	0.06
HDL	43.20 ± 12.31	43.38 ± 12.80	42.63 ± 10.67	0.51
Fasting blood sugar	129.35 ± 62.19	130.65 ± 94.73	125.56 ± 36.34	0.12
CRI-I	3.99 ± 1.46	4.00 ± 1.28	2.97 ± 1.87	0.26
CRI-II	2.45 ± 1.44	2.45 ± 1.41	2.97 ± 2.39	0.35
AIP	0.41 ± 0.28	0.43 ± 0.28	0.38 ± 0.20	0.02 ^c
TyG Index	8.78 ± 0.72	8.81 ± 0.73	8.66 ± 0.66	0.001 ^c
Non-HDL cholesterol	122.16 ± 62.95	122.76 ± 44.97	120.73 ± 31.99	0.02 ^c

Abbreviations: TG, triglycerides; LDL, low-density lipoprotein; HDL, high-density lipoprotein; TyG Index, Triglyceride-Glucose Index; AIP, Atherogenic Index of Plasma; CRI-I, Castelli's Risk Index I; CRI-II, Castelli's Risk Index II.

^a Values are expressed as mean ± SD

^b Statistical tests used in the table is Mann-Whitney test.

^c P < 0.05 was considered statistically significant.

DM in these individuals was 17% lower than in non-consumers, primarily due to reduced body mass and smaller waist circumference. Researchers attributed the lower blood sugar levels in opium users to lower body mass and less abdominal obesity (22).

In our study, the history of hypertension was less frequent in the opium-consuming group. The blood pressure levels in the opium group were also lower, which was consistent with our study, but in the study by Hamrah et al. (1), elevated blood pressure was reported

among opium addicts. This discrepancy may indicate the impact of dosage and duration of opium use on blood pressure regulation; thus, it reflects the complexity of interpreting cardiovascular outcomes among opium users. Low doses and short-term administration of opium typically lower blood pressure through vasodilation and reduced sympathetic tone, while long-term opium use can lead to increased plasma homocysteine, higher oxidative stress, decreased opioid receptor availability, and ultimately increased blood pressure (1).

In this study, triglyceride levels were significantly lower in opium consumers. Additionally, the studies by Asgary et al. (23) and Fatemi et al. (15) reported higher triglyceride levels in the non-opium group compared to the opium-consuming group. This finding underlines the relationship between opium consumption and lipid profiles, suggesting that lower BMI in opium users may contribute to their favorable triglyceride levels. However, it is important to consider potential confounding factors or selection biases that might influence these results. Factors such as dietary habits, levels of physical activity, and other lifestyle choices may have skewed our findings. Further investigation is necessary to determine the extent to which these factors impact lipid profiles in both opium consumers and non-consumers.

Regarding the suggestion that opium could be considered a significant management strategy for reducing cardiac risk factors, we must clarify that while our findings indicate a correlation between opium use and lower triglyceride levels, this does not imply causation or advocate for opium as a treatment modality. The complexities surrounding the consumption of opium, along with its associated health risks, necessitate a cautious interpretation of these results. To strengthen our manuscript, we acknowledge the need for a critical discussion addressing potential mechanisms, limitations, and alternative explanations for our findings. This would provide a more comprehensive understanding of the dynamics at play and ensure that the interpretation of our results is accurate and not misleading.

In our study, there were no significant differences in cholesterol and LDL levels between non-consumers and consumers of opium; however, in the studies by Hamrah et al. (1), Fatemi et al. (15), and Kazemi et al. (8),

cholesterol levels were lower in the opium-consuming group compared to non-consumers. In the studies conducted by Aghadavoudi et al. (6), Fatemi et al. (15), and Liew et al. (21), LDL levels were higher in non-consumers compared to users. Dietary habits, socioeconomic status, and unhealthy lifestyle choices may influence lipid profiles and LDL levels in individuals. In the present study, HDL levels did not show significant statistical differences between non-opium users and opium users, which was similar to Liew's study (21).

In our study, the AIP, TyG, and non-HDL were significantly lower in the opium-consuming group compared to the non-consumers. We did not find any similar studies comparing these indices in opium users. This suggests a novel area for further research to comprehensively understand the implications of these indices in assessing cardiovascular risks associated with opium use. Given that in this study, the rate of smoking had a significant positive correlation with opium use (26.2% smokers in the opium group vs. 5.8% smokers in the non-opium group), we explored related studies concerning these new lipid indices among smokers. Baek et al. conducted a study in Korea comparing the TyG Index among the subjects. They found that in smokers or alcohol users, this index was higher compared to non-smokers or non-alcohol users, and those who consumed both (smoking and alcohol) showed significantly higher levels (24). Tobacco and cigarette smoke can produce pro-inflammatory toxic substances. Additionally, oxidative stress and mitochondrial dysfunction in smokers can reduce peripheral insulin and increase sensitivity to it. Direct dysfunction of β -cells has also been reported in smokers (24).

The molecular mechanism of opium in the pathogenesis of CAD remains unclear. Momeni-Moghaddam et al., in a case-control study, compared the expression of receptors CD36, CD68, CD9 as well as levels of inflammatory factors tumor necrosis factor alpha (TNF- α), interferon gamma (IFN- γ), and malondialdehyde (MDA) in three groups (30 addicted CAD patients, 30 non-addicted CAD, and 17 healthy opium users). The results showed that only inflammatory factors were elevated in addicted CAD patients. This finding suggests the need for further investigation into the inflammatory pathways linked to opium use and CAD, which might isolate opium as an

independent risk factor despite lower levels of traditional cardiovascular risk factors (25).

5.1. Limitations

This study has several limitations. Firstly, the reliance on self-reported data regarding opium consumption may introduce recall bias. Secondly, the cross-sectional design limits the ability to establish causal relationships. Lastly, the study was conducted in a single center, which may affect the generalizability of the findings to other populations. Additionally, we were unable to assess confounders such as diet, alcohol consumption, and exercise, which may influence the results.

5.2. Conclusions

In conclusion, while the current study suggests that opium consumption may present a distinct profile regarding cardiovascular risk factors, caution should be exercised in the universal interpretation of these results. Further research, particularly mechanistic studies, is essential to confirm these findings and clarify opium's role as an independent risk factor for cardiovascular diseases across diverse populations and settings. Such investigations could significantly enhance our understanding of the complexities surrounding opium use and cardiovascular health. To improve the understanding and management of the intricate relationship between opium use and cardiovascular health, we advocate for interdisciplinary collaboration. Engaging with addiction specialists will provide a better context for our findings within the framework of addiction behaviors. Moreover, collaborating with public health experts can facilitate the development of comprehensive intervention strategies that address the multifaceted challenges associated with opium consumption and its health implications.

Acknowledgements

This article is derived from the results of a medical student thesis in Birjand University of medical sciences and utilizes data from the national cardiovascular disease registry (N-PROVE), which is conducted by the The Iranian Network of Cardiovascular Research (INCVR) and Isfahan Cardiovascular Research Institute. The

authors thank all the Razi Hospital Clinical Research Development Unit.

Footnotes

Authors' Contribution: S. S. Sh., M. H., S. A. M. B., N. A. S. Kh. B., F. N., A. Kh. and T. K. contributed to the study design and data collection. M. H., S. A. M. B., and N. A. were involved in the data collection process. S. S. Sh., M. H., and T. K. contributed to the interpretation of results. Data analysis was performed by A. Kh. and F. N. Writing and submission of the manuscript were handled by S. S. Sh., F. N., and T. K. All authors approved the final version of the manuscript.

Conflict of Interests Statement: The authors have no real or potential conflicts of interest to declare.

Data Availability: The dataset presented in the study is available on request from the corresponding author during submission or after publication.

Ethical Approval: The study is approved under the ethical approval code: [IR.BUMS.REC.1401.171](#).

Funding/Support: The funding was provided by the Research and Technology Deputy of Birjand University of Medical Sciences.

Informed Consent: Eligible patients provided informed consent before participating in the study.

References

1. Hamrah MS, Hamrah MH, Hamrah MH, Dahi T, Hamrah AT, Zarghami F, et al. Impact of opium use on the conventional coronary artery risk factors among outpatients in Afghanistan: A case-control study In Andkhoy City. *Pak J Med Health Sci*. 2021;**15**(1):461-7.
2. Amirpour A, Kermani-Alghoraishi M, Sattar F, Roohafza H, Shahabi J, Zavar R, et al. Does Opioid Addiction Influence Clinical and Angiographic Outcomes in STEMI Patients Undergoing Emergency PCI? *Adv Biomed Res*. 2023;**12**:12. [PubMed ID: [36926439](#)]. [PubMed Central ID: [PMC10012017](#)]. https://doi.org/10.4103/abr.abr_295_21.
3. Khademi H, Malekzadeh R, Pourshams A, Jafari E, Salahi R, Semnani S, et al. Opium use and mortality in Golestan Cohort Study: prospective cohort study of 50,000 adults in Iran. *BMJ*. 2012;**344**. e2502. [PubMed ID: [22511302](#)]. [PubMed Central ID: [PMC3328545](#)]. <https://doi.org/10.1136/bmj.e2502>.
4. Shad B, Hasandokht T, Salari A, Pour S, Tirani H, Rajabi E. Does opium have benefit for coronary artery disease? A systematic review. *Res Cardiovascular Med*. 2018;**7**(2). https://doi.org/10.4103/rcm.rcm_12_17.
5. Gaidai O, Cao Y, Loginov S. Global Cardiovascular Diseases Death Rate Prediction. *Curr Probl Cardiol*. 2023;**48**(5):101622. [PubMed ID: [36724816](#)]. <https://doi.org/10.1016/j.cpcardiol.2023.101622>.

6. Aghadavoudi O, Eizadi-Mood N, Najarzagdegan MR. Comparing cardiovascular factors in opium abusers and non-users candidate for coronary artery bypass graft surgery. *Adv Biomed Res.* 2015;**4**:12. [PubMed ID: 25625118]. [PubMed Central ID: PMC4300596]. <https://doi.org/10.4103/2277-9175.148294>.
7. Safaïi N, Kazemi B. Effect of opium use on short-term outcome in patients undergoing coronary artery bypass surgery. *Gen Thorac Cardiovasc Surg.* 2010;**58**(2):62-7. [PubMed ID: 20155341]. <https://doi.org/10.1007/s11748-009-0529-7>.
8. Kazemi M, Bazayr M, Naghizadeh MM, Dehghan A, Rahimabadi MS, Chijan MR, et al. Lipid profile dysregulation in opium users based on Fasa PERSIAN cohort study results. *Sci Rep.* 2021;**11**(1):12058. [PubMed ID: 34103610]. [PubMed Central ID: PMC8187592]. <https://doi.org/10.1038/s41598-021-91533-4>.
9. Lemieux I, Lamarche B, Couillard C, Pascot A, Cantin B, Bergeron J, et al. Total cholesterol/HDL cholesterol ratio vs LDL cholesterol/HDL cholesterol ratio as indices of ischemic heart disease risk in men: the Quebec Cardiovascular Study. *Arch Intern Med.* 2001;**161**(22):2685-92. [PubMed ID: 11732933]. <https://doi.org/10.1001/archinte.161.22.2685>.
10. Hermans MP, Fruchart J. Reducing residual vascular risk in patients with atherogenic dyslipidemia: where do we go from here? *Clin Lipidol.* 2017;**5**(6):811-26. <https://doi.org/10.2217/clp.10.65>.
11. Raja V, Aguiar C, Alsayed N, Chibber YS, ElBadawi H, Ezhov M, et al. Non-HDL-cholesterol in dyslipidemia: Review of the state-of-the-art literature and outlook. *Atherosclerosis.* 2023;**383**:117312. [PubMed ID: 37826864]. <https://doi.org/10.1016/j.atherosclerosis.2023.117312>.
12. Ding X, Wang X, Wu J, Zhang M, Cui M. Triglyceride-glucose index and the incidence of atherosclerotic cardiovascular diseases: a meta-analysis of cohort studies. *Cardiovasc Diabetol.* 2021;**20**(1):76. [PubMed ID: 33812373]. [PubMed Central ID: PMC8019501]. <https://doi.org/10.1186/s12933-021-01268-9>.
13. Nakhaee S, Ghasemi S, Karimzadeh K, Zamani N, Alinejad-Mofrad S, Mehrpour O. The effects of opium on the cardiovascular system: a review of side effects, uses, and potential mechanisms. *Subst Abuse Treat Prev Policy.* 2020;**15**(1):30. [PubMed ID: 32303254]. [PubMed Central ID: PMC7164148]. <https://doi.org/10.1186/s13011-020-00272-8>.
14. Marmor M, Penn A, Widmer K, Levin RI, Maslansky R. Coronary artery disease and opioid use. *Am J Cardiol.* 2004;**93**(10):1295-7. [PubMed ID: 15135709]. <https://doi.org/10.1016/j.amjcard.2004.01.072>.
15. Fatemi SS, Hasanazadeh M, Arghami A, Sargolzaee MR. Lipid Profile Comparison between Opium Addicts and Non-Addicts. *J Teh Univ Heart Ctr.* 2008;**3**:169-72.
16. Mami S, Eghbali M, Cheraghi J, Mami F, Borujeni MP, Salati AP. Effect of opium addiction on some serum parameters in rabbit. *Glob Vet.* 2011;**7**:310-4.
17. Najafipour H, Masoomi M, Shahesmaeili A, Haghdooost AA, Afshari M, Nasri HR, et al. Effects of opium consumption on coronary artery disease risk factors and oral health: Results of Kerman Coronary Artery Disease Risk factors Study a population-based survey on 5900 subjects aged 15-75 years. *Int J Prev Med.* 2015;**6**:42. [PubMed ID: 26097671]. [PubMed Central ID: PMC4455126]. <https://doi.org/10.4103/2008-7802.157470>.
18. Givi M, Sarrafzadegan N, Garakyaraghi M, Yadegarfar G, Sadeghi M, Khosravi A, et al. Persian Registry of cardiovascular disease (PROVE): Design and methodology. *ARYA Atherosclerosis.* 2017;**13**(5):236.
19. Davoodi G, Sadeghian S, Akhondzadeh S, Darvish S, Alidoosti M, Amirzadegan A. Comparison of specifications, short term outcome and prognosis of acute myocardial infarction in opium dependent patients and nondependents. *J Tehran Univ Heart Center.* 2006;**1**(1):48-53.
20. Sheikhy A, Fallahzadeh A, Nayeberad S, Nalini M, Sadeghian S, Pashang M, et al. Opium consumption and long-term outcomes of CABG surgery in patients without modifiable risk factors. *Front Surg.* 2023;**10**:1047807. [PubMed ID: 36874455]. [PubMed Central ID: PMC9982127]. <https://doi.org/10.3389/fsurg.2023.1047807>.
21. Liew SM, Chowdhury EK, Ernst ME, Gilmartin-Thomas J, Reid CM, Tonkin A, et al. Prescribed opioid use is associated with adverse cardiovascular outcomes in community-dwelling older persons. *ESC Heart Fail.* 2022;**9**(6):3973-84. [PubMed ID: 35985663]. [PubMed Central ID: PMC9773735]. <https://doi.org/10.1002/ehf2.14101>.
22. Nalini M, Poustchi H, Roshandel G, Kamangar F, Khoshnia M, Gharavi A, et al. Association Between Incident Type 2 Diabetes and Opium Use: Mediation by Body Mass and Adiposity. *Am J Epidemiol.* 2023;**192**(12):2050-62. [PubMed ID: 37552966]. [PubMed Central ID: PMC10691200]. <https://doi.org/10.1093/aje/kwad166>.
23. Asgary S, Sarrafzadegan N, Naderi GA, Rozbehani R. Effect of opium addiction on new and traditional cardiovascular risk factors: do duration of addiction and route of administration matter? *Lipids Health Dis.* 2008;**7**:42. [PubMed ID: 18980684]. [PubMed Central ID: PMC2588593]. <https://doi.org/10.1186/1476-511X-7-42>.
24. Baek W, Lee JW, Lee HS, Han D, Choi SY, Chun EJ, et al. Concurrent smoking and alcohol consumers had higher triglyceride glucose indices than either only smokers or alcohol consumers: a cross-sectional study in Korea. *Lipids Health Dis.* 2021;**20**(1):49. [PubMed ID: 33975592]. [PubMed Central ID: PMC8111749]. <https://doi.org/10.1186/s12944-021-01472-2>.
25. Momeni-Moghaddam MA, Asadikaram G, Masoumi M, Sadeghi E, Akbari H, Abolhassani M, et al. Opium may affect coronary artery disease by inducing inflammation but not through the expression of CD9, CD36, and CD68. *J Investig Med.* 2023;**71**(3):191-201. [PubMed ID: 36708288]. <https://doi.org/10.1177/10815589221145030>.